Related Experiment Video
Updated: Jul 11, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Investigation and treatment of hypertrophic cardiomyopathy
1The Heart Hospital, University College, London. pelliott@doctors.org.uk
Insights
Hypertrophic cardiomyopathy is a common genetic heart disease causing left ventricular hypertrophy. Risk stratification and genetic counseling are crucial for managing its varied clinical course and complications.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac condition.
- It is characterized by left ventricular hypertrophy unexplained by other cardiac or systemic diseases.
- HCM presents with a wide spectrum of clinical manifestations and prognoses.
Purpose of the Study:
- To provide an overview of hypertrophic cardiomyopathy.
- To discuss its clinical definition, heterogeneous course, and complications.
- To highlight the importance of genetic counseling and risk stratification.
Main Methods:
- Clinical definition of HCM based on left ventricular hypertrophy.
- Assessment of disease heterogeneity and clinical course.
- Review of disease-related complications and risk factors.
Main Results:
- HCM affects individuals differently, ranging from asymptomatic cases to severe exercise limitation and arrhythmias.
- Annual complication rates (sudden death, heart failure, stroke) are approximately 1-2%.
- Individual patient risk is influenced by age, disease severity, and etiology.
Conclusions:
- Genetic counseling and clinical risk stratification are essential for all HCM patients.
- Specific interventions like septal ablation, myectomy, or ICDs are indicated for subsets of patients.
- Understanding disease variability is key to effective management.
Abstract:
Hypertrophic cardiomyopathy is a common genetically transmitted disease, defined clinically by the presence of left ventricular hypertrophy in the absence of loading conditions sufficient to cause the observed degree of hypertrophy. The disease has a heterogeneous clinical course, with many patients having few cardiovascular symptoms and others profound exercise limitation and recurrent arrhythmia. The overall annual rate of disease-related complications such as sudden death, end-stage heart failure and fatal stroke is approximately 1-2%, but risk in individual patients varies as a function of age, disease severity and the underlying cause of the hypertrophy. Genetic counselling and clinical risk stratification are relevant for all patients. Subsets of patients require septal alcohol ablation, septal myectomy and implantable cardioverter defibrillators.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Myocarditis III: Medical Management

